Lead Sponsor

Kyowa Kirin Co., Ltd.

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•Personally submitted written voluntary informed consent to participate in the study
•Patients with a diagnosis of parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.
•Corrected serum calcium level is \> 11.3 mg/dL at screening.

•Patients receiving cinacalcet hydrochloride within 2 weeks before screening
•Patients diagnosed with hypercalcemia associated with malignant tumors other than parathyroid carcinoma.
•Severe heart disease
•Severe hepatic dysfunction
•Uncontrolled hypertension and/or diabetes
•Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening